类风湿关节炎再治疗时利妥昔单抗剂量对维持治疗与严重感染风险的影响
基于AIR注册队列的全国性前瞻性观察研究,纳入1278例首次标准剂量利妥昔单抗后再次治疗的患者,比较标准剂量组与减量组的5年维持率和严重感染率;减量再治疗未显著改变5年维持率,但累积剂量更低且严重感染率显著更低。
要点
- 减量再治疗组5年维持率53.8% vs 标准剂量组55.5%,调整后无显著差异(HR=1.03;95%CI:0.81,1.30)。
- 减量组累积再治疗剂量1.4(0.6)g/年 vs 标准剂量组2.3(1.0)g/年,P<0.001。
- 减量组严重感染率显著低于标准剂量组(调整后HR=0.50;95%CI:0.27,0.92;P=0.02)。
核心结论
- 减量利妥昔单抗再治疗未改变RA患者5年维持率,但实现39%总剂量减少且严重感染率更低。
研究设计与样本
- 自身免疫与利妥昔单抗(AIR)注册为全国性前瞻性观察队列,研究利妥昔单抗治疗RA的长期安全性与有效性。
- 纳入AIR注册中首次标准剂量(1000 mg×2)利妥昔单抗后再次治疗的患者共1278例。
- 按首次再治疗(即第二疗程)剂量分为标准剂量组1093例(85.5%)与减量组185例(14.5%)。
- 比较两组再治疗期间5年维持率与严重感染率,采用逆概率治疗加权倾向评分调整法分析。
主要发现
- 标准剂量组与减量组5年维持率分别为55.5%与53.8%,调整分析无显著差异(HR=1.03;95%CI:0.81,1.30)。
- 减量组再治疗累积剂量1.4(0.6)g/年 vs 标准剂量组2.3(1.0)g/年,P<0.001。
- 减量组严重感染率显著低于标准剂量组(调整后HR=0.50;95%CI:0.27,0.92;P=0.02)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate maintenance of rituximab (RTX) in RA patients re-treated with reduced doses compared with standard dose in a real life setting. METHODS: The Autoimmunity and Rituximab (AIR) registry is a nationwide prospective observational cohort investigating the long-term safety and efficacy of RTX in RA. The present study included patients from the AIR registry that have been re-treated with RTX after a first course of RTX standard dose (1000 mg × 2). Two groups were defined according to dose of RTX of the first retreatment course (i.e. second course): standard dose group and reduced dose group. Five years' maintenance and rate of serious infections of the retreatment period were compared between standard dose and reduced dose groups. Analyses used the inverse probability of treatment weighting propensity score adjusted method. RESULTS: Among the 1986 patients from the AIR registry, 1278 were included, 1093 (85.5%) treated with standard dose and 185 (14.5%) with reduced doses. Maintenance of RTX at 5 years in the standard and reduced groups was 55.5 and 53.8%, respectively, and did not significantly differ between groups in adjusted analyses (hazard ratio = 1.03; 95% CI: 0.81, 1.30), but the cumulative RTX dose received for retreatment [1.4 (0.6) vs 2.3 (1.0) g/year, P < 0.001] and the rate of serious infections were significantly lower in the reduced dose group (adjusted hazard ratio = 0.50; 95% CI: 0.27, 0.92; P = 0.02). CONCLUSION: Use of reduced doses of RTX for retreatment did not alter the maintenance of RTX at 5 years in RA patients, but allowed a 39% total dose reduction and a lower rate of serious infections.
引用
- Henry J, Gottenberg JE, Rouanet S, et al. Doses of rituximab for retreatment in rheumatoid arthritis: influence on maintenance and risk of serious infection. Rheumatology (Oxford). 2018. PMID: 29267905. doi:10.1093/rheumatology/kex446
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。